Deep Neuromuscular Blockade in Strabismus Surgery

April 21, 2026 updated by: Young-Eun Jang, Seoul National University Hospital

The Effect of the Deep Neuromuscular Block on the Refraction and the Oculocardiac Reflex During Strabismus Surgery in Pediatric Patients - a Prospective Randomized Controlled Trial

The purpose of this study is to determine if inducing a moderate or greater neuromuscular block (TOF count 0-3) when performing a neuromuscular block in pediatric patients aged 3 to 18 years undergoing strabismus surgery under general anesthesia can reduce the incidence of the oculocardiac reflex.

Study Overview

Study Type

Interventional

Enrollment (Actual)

201

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Seoul, South Korea
        • Seoul National University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Pediatric patients between the ages of 3 and 18 who are American Society of Anesthesiologists physical classification (ASA) I, II, or III scheduled for strabismus surgery under general anesthesia.

Exclusion Criteria:

  • Patients with underlying cardiovascular disease
  • Patients with preoperative electrocardiograms showing conduction disturbances
  • Patients with neuromuscular disease
  • Any other patient who, in the opinion of the investigator, is not a good candidate for the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: block group
  • Maintaining moderate to deep neuromuscular blockade during an intraoperative period (Train-of-four 0-3, post-tetanic count > 1)
  • Rocuronium (intravenous, 1.0 mg/kg)
  • Maintaining moderate to deep neuromuscular blockade during an intraoperative period (Train-of-four 0-3 count, post-tetanic count > 1)
  • Rocuronium (intravenous, 1.0 mg/kg at induction period)
Active Comparator: control group
  • Maintaining shallow to minimal neuromuscular blockade during an intraoperative period (Train-of-four 4, post-tetanic count < 0.9)
  • Rocuronium (intravenous, 0.3 mg/kg)
  • Maintaining shallow to minimal neuromuscular blockade during an intraoperative period (Train-of-four 4, post-tetanic count < 0.9)
  • Rocuronium (intravenous, 0.3 mg/kg at induction period)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The incidence of grade 2 or greater oculocardiac reflex (during strabismus surgery)
Time Frame: Day 1, During general anesthesia for strabismus surgery (within 2 hours).
> 20% reduction in heart rate during strabismus surgery
Day 1, During general anesthesia for strabismus surgery (within 2 hours).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The incidence of hypotension
Time Frame: During general anesthesia for strabismus surgery (within 2 hour)
The incidence of hypotension, defined as a drop to 20% or more of baseline mean blood pressure
During general anesthesia for strabismus surgery (within 2 hour)
Postoperative nausea/vomiting
Time Frame: From extubation to post-anesthesia care unit stay (within 1 hour)
Presence of postoperative nausea/vomiting as assessed in the recovery room
From extubation to post-anesthesia care unit stay (within 1 hour)
Results from a refraction test before strabismus surgery
Time Frame: Before strabismus surgery (within 12 month)
Results from a refraction test before strabismus surgery measured at outpatient clinic
Before strabismus surgery (within 12 month)
Results from a refraction test at strabismus surgery
Time Frame: During general anesthesia for strabismus surgery (within 2 hour)
Results from a refraction test during strabismus surgery
During general anesthesia for strabismus surgery (within 2 hour)
The incidence of grade 1 oculocardiac reflex (during strabismus surgery)
Time Frame: Day 1, During general anesthesia for strabismus surgery (within 2 hours).
< 20% reduction in heart rate during general anesthesia for strabismus surgery (within 2 hours).
Day 1, During general anesthesia for strabismus surgery (within 2 hours).
The incidence of grade 3 or greater oculocardiac reflex (during strabismus surgery)
Time Frame: During general anesthesia for strabismus surgery (usually within 2 hour)
> 30% decrease in heart rate (moderate oculocardiac reflex) during strabismus surgery
During general anesthesia for strabismus surgery (usually within 2 hour)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 2, 2024

Primary Completion (Actual)

November 26, 2025

Study Completion (Actual)

November 26, 2025

Study Registration Dates

First Submitted

May 22, 2023

First Submitted That Met QC Criteria

May 22, 2023

First Posted (Actual)

May 31, 2023

Study Record Updates

Last Update Posted (Actual)

April 23, 2026

Last Update Submitted That Met QC Criteria

April 21, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Strabismus

Clinical Trials on moderate to deep neuromuscular blockade

Subscribe